Enterprise Value

462.3M

Cash

208.2M

Avg Qtr Burn

-21.42M

Short % of Float

21.95%

Insider Ownership

9.53%

Institutional Own.

88.37%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ORIC-114 (EGFR/HER2 Inhibitor) Details
Solid tumor/s, Advanced malignancies, Cancer

Phase 1b

Data readout

ORIC-533 (CD73 Inhibitor) Details
Multiple myeloma, Cancer

Phase 1b

Update

ORIC-944 (PRC2 inhibitor) Details
Prostate cancer, Cancer

Phase 1b

Update

Failed

Discontinued

ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details
Solid tumor/s, Muscle control disorder, Spasticity, Cancer

Failed

Discontinued